Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708639 | 0.93 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL22922041 | 0.89 | MEN1 (0.49) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL14268284 | 0.86 | MEN1 (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11024894 | 0.82 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL17354084 | 0.82 | MEN1 (0.34) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL769949 | 0.82 | MEN1 (0.34) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23014841 | 0.81 | KMT2A (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL16376197 | 0.81 | MEN1 (0.56) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13181236 | 0.80 | MEN1 (0.40) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23544814 | 0.78 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | MEN1 2869/4885KMT2A 3715/4885KDM4C 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.